Idacio, which has been on the Spanish market for a year, is a biosimilar of adalimumab indicated for rheumatological, dermatological and gastroenterological pathologies. The healthcare company celebrates the good reception of Idacio and works to develop new biosimilars in the fields of oncology and immunology.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
